ANAPTYSBIO, INC. Operating Income
ANAPTYSBIO, INC. (ANAB) reported Operating Income of $32.32 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-09-21
- ANAPTYSBIO, INC. operating income (loss) for the quarter ending 2026-06-30 was $66.96M.
- ANAPTYSBIO, INC. operating income (loss) for the quarter ending 2026-03-31 was -$34.64M.
- ANAPTYSBIO, INC. operating income (loss) for the quarter ending 2025-12-31 was $245.91M, a 43.44% increase year-over-year.
- ANAPTYSBIO, INC. operating income (loss) for the quarter ending 2025-09-30 was $34.70M.
- ANAPTYSBIO, INC. operating income (loss) for fiscal 2025 was $226.90M, a 243.00% increase from fiscal 2024.
- ANAPTYSBIO, INC. operating income (loss) for fiscal 2024 was $66.15M.
- ANAPTYSBIO, INC. operating income (loss) for fiscal 2023 was -$164.41M.
- ANAPTYSBIO, INC. operating income (loss) for fiscal 2022 was -$115.15M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $66.96M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $32.32M 10-KT · filed 2026-09-21 | $278.23M derived: sum of 3 quarters · filed 2026-09-21 | $312.93M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2026-03-31 | -$34.64M 10-Q · filed 2026-05-12 | $211.27M derived: sum of 2 quarters · filed 2026-09-21 | $245.97M derived: sum of 3 quarters · filed 2026-09-21 | $219.80M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-12-31 | $245.91M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $280.61M derived: sum of 2 quarters · filed 2026-09-21 | $254.44M derived: sum of 3 quarters · filed 2026-09-21 | $226.90M 10-KT · filed 2026-09-21 | $47.90M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $34.70M 10-Q · filed 2025-11-04 | $8.53M derived: sum of 2 quarters · filed 2025-11-04 | -$19.00M 10-Q · filed 2025-11-04 | $152.43M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-06-30 | -$26.17M 10-Q · filed 2025-08-06 | $43.47M 10-KT · filed 2026-09-21 | -$53.71M 10-Q · filed 2025-08-06 | $117.72M derived: sum of 3 quarters · filed 2026-09-21 | $94.97M derived: sum of 4 quarters · filed 2026-09-21 | |
| 2025-03-31 | -$27.54M 10-Q · filed 2026-05-12 | $143.89M derived: sum of 2 quarters · filed 2026-09-21 | $121.14M derived: sum of 3 quarters · filed 2026-09-21 | $80.81M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2024-12-31 | $171.43M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $148.67M derived: sum of 2 quarters · filed 2026-09-21 | $108.35M derived: sum of 3 quarters · filed 2026-09-21 | $66.15M 10-KT · filed 2026-09-21 | -$114.95M 10-K · filed 2025-02-27 | |
| 2024-09-30 | -$22.76M 10-Q · filed 2025-11-04 | -$63.08M derived: sum of 2 quarters · filed 2025-11-04 | -$105.28M 10-Q · filed 2025-11-04 | -$147.41M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | -$40.32M 10-Q · filed 2025-08-06 | -$82.52M 10-Q · filed 2025-08-06 | -$124.66M derived: sum of 3 quarters · filed 2026-03-03 | -$162.39M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | -$42.20M 10-Q · filed 2025-05-05 | -$84.34M derived: sum of 2 quarters · filed 2026-03-03 | -$122.07M derived: sum of 3 quarters · filed 2026-03-03 | -$162.21M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2023-12-31 | -$42.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$79.87M derived: sum of 2 quarters · filed 2026-03-03 | -$120.01M derived: sum of 3 quarters · filed 2026-03-03 | -$164.41M 10-K · filed 2026-03-03 | ||
| 2023-09-30 | -$37.73M 10-Q · filed 2024-11-05 | -$77.88M derived: sum of 2 quarters · filed 2024-11-05 | -$122.28M 10-Q · filed 2024-11-05 | -$148.25M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | -$40.14M 10-Q · filed 2024-08-05 | -$84.54M 10-Q · filed 2024-08-05 | -$110.52M derived: sum of 3 quarters · filed 2025-02-27 | -$140.15M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | -$44.40M 10-Q · filed 2024-05-09 | -$70.37M derived: sum of 2 quarters · filed 2025-02-27 | -$100.01M derived: sum of 3 quarters · filed 2025-02-27 | -$127.81M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | -$25.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$55.61M derived: sum of 2 quarters · filed 2025-02-27 | -$83.41M derived: sum of 3 quarters · filed 2025-02-27 | -$115.15M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | -$29.63M 10-Q · filed 2023-11-02 | -$57.43M derived: sum of 2 quarters · filed 2023-11-02 | -$89.18M 10-Q · filed 2023-11-02 | -$120.34M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-06-30 | -$27.80M 10-Q · filed 2023-08-07 | -$59.55M 10-Q · filed 2023-08-07 | -$90.70M derived: sum of 3 quarters · filed 2024-03-11 | -$97.47M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-03-31 | -$31.75M 10-Q · filed 2023-05-11 | -$62.91M derived: sum of 2 quarters · filed 2024-03-11 | -$69.67M derived: sum of 3 quarters · filed 2024-03-11 | -$70.20M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2021-12-31 | -$31.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$37.92M derived: sum of 2 quarters · filed 2024-03-11 | -$38.45M derived: sum of 3 quarters · filed 2024-03-11 | -$56.81M 10-K · filed 2024-03-11 | ||
| 2021-09-30 | -$6.76M 10-Q · filed 2022-11-08 | -$7.30M derived: sum of 2 quarters · filed 2022-11-08 | -$25.66M 10-Q · filed 2022-11-08 | $7.69M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | -$533.00K 10-Q · filed 2022-08-08 | -$18.89M 10-Q · filed 2022-08-08 | $14.45M derived: sum of 3 quarters · filed 2023-03-01 | -$9.88M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | -$18.36M 10-Q · filed 2022-05-04 | $14.98M derived: sum of 2 quarters · filed 2023-03-01 | -$9.35M derived: sum of 3 quarters · filed 2023-03-01 | -$31.99M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $33.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $9.01M derived: sum of 2 quarters · filed 2023-03-01 | -$13.63M derived: sum of 3 quarters · filed 2023-03-01 | -$23.88M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | -$24.34M 10-Q · filed 2021-11-04 | -$46.97M derived: sum of 2 quarters · filed 2021-11-04 | -$57.22M 10-Q · filed 2021-11-04 | -$79.48M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | -$22.64M 10-Q · filed 2021-08-09 | -$32.89M 10-Q · filed 2021-08-09 | -$55.15M derived: sum of 3 quarters · filed 2021-08-09 | -$88.89M derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | -$10.25M 10-Q · filed 2021-05-04 | -$32.51M derived: sum of 2 quarters · filed 2021-05-04 | -$66.26M derived: sum of 3 quarters · filed 2021-05-04 | -$92.91M derived: sum of 4 quarters · filed 2021-05-04 | ||
| 2019-12-31 | -$22.26M 10-K · filed 2020-03-02 | -$56.00M derived: sum of 2 quarters · filed 2020-11-04 | -$82.66M derived: sum of 3 quarters · filed 2020-11-04 | -$107.43M 10-K · filed 2022-03-07 | ||
| 2019-09-30 | -$33.74M 10-Q · filed 2020-11-04 | -$60.40M derived: sum of 2 quarters · filed 2020-11-04 | -$85.17M 10-Q · filed 2020-11-04 | -$104.84M derived: sum of 4 quarters · filed 2020-11-04 | ||
| 2019-06-30 | -$26.66M 10-Q · filed 2020-08-10 | -$51.43M 10-Q · filed 2020-08-10 | -$71.09M derived: sum of 3 quarters · filed 2020-08-10 | -$87.98M derived: sum of 4 quarters · filed 2020-08-10 | ||
| 2019-03-31 | -$24.77M 10-Q · filed 2020-05-06 | -$44.44M derived: sum of 2 quarters · filed 2020-05-06 | -$61.32M derived: sum of 3 quarters · filed 2020-05-06 | -$75.74M derived: sum of 4 quarters · filed 2020-05-06 | ||
| 2018-12-31 | -$19.66M 10-K · filed 2020-03-02 | -$36.55M derived: sum of 2 quarters · filed 2020-03-02 | -$50.97M derived: sum of 3 quarters · filed 2020-03-02 | -$66.72M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$16.89M 10-K · filed 2020-03-02 | -$31.30M derived: sum of 2 quarters · filed 2020-03-02 | -$47.06M 10-Q · filed 2019-11-08 | -$54.21M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | -$14.41M 10-K · filed 2020-03-02 | -$30.17M 10-Q · filed 2019-08-08 | -$37.32M derived: sum of 3 quarters · filed 2020-03-02 | -$46.41M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-03-31 | -$15.76M 10-K · filed 2020-03-02 | -$22.91M derived: sum of 2 quarters · filed 2020-03-02 | -$32.00M derived: sum of 3 quarters · filed 2020-03-02 | -$34.55M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2017-12-31 | -$7.15M 10-K · filed 2019-02-28 | -$16.24M derived: sum of 2 quarters · filed 2019-02-28 | -$18.79M derived: sum of 3 quarters · filed 2019-02-28 | -$28.78M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | -$9.09M 10-K · filed 2019-02-28 | -$11.64M derived: sum of 2 quarters · filed 2019-02-28 | -$21.63M 10-Q · filed 2018-11-08 | -$24.80M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2017-06-30 | -$2.56M 10-K · filed 2019-02-28 | -$12.54M 10-Q · filed 2018-08-07 | -$15.72M derived: sum of 3 quarters · filed 2019-02-28 | -$16.79M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2017-03-31 | -$9.99M 10-K · filed 2019-02-28 | -$13.16M derived: sum of 2 quarters · filed 2019-02-28 | -$14.24M derived: sum of 3 quarters · filed 2019-02-28 | -$11.87M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2016-12-31 | -$3.17M 10-K · filed 2018-03-05 | -$4.25M derived: sum of 2 quarters · filed 2018-03-05 | -$1.89M derived: sum of 3 quarters · filed 2018-03-05 | -$3.02M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | -$1.07M 10-K · filed 2018-03-05 | $1.29M derived: sum of 2 quarters · filed 2018-03-05 | $149.00K 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $2.36M 10-K · filed 2018-03-05 | $1.22M 10-Q · filed 2017-08-10 | ||||
| 2016-03-31 | -$1.14M 10-K · filed 2018-03-05 | |||||
| 2015-12-31 | -$3.32M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |